CHARM · 252LH301
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A phase 3, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy and safety of intravenous BIIB093 (glibenclamide) for severe brain oedema following malignant hemispheric infarction (CHARM), including modified Rankin Scale and mortality outcomes. EudraCT: 2017-004854-41.
Sponsor: BIOGEN
Phase: III
Area: Vascular neurology